P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2018

  • ID: 4590349
  • Drug Pipelines
  • 60 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Asana BioSciences LLC
  • Bayer AG
  • Integral Molecular Inc
  • Merck & Co Inc
  • Pfizer Inc
  • Shionogi & Co Ltd
  • MORE
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2018

Summary:

P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.

P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 3 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Respiratory, Genito Urinary System And Sex Hormones, Women's Health, Cardiovascular and Ophthalmology which include indications Chronic Cough, Pain, Endometriosis, Inflammatory Pain, Visceral Pain, Alzheimer's Disease, Chronic Pain, Cough, Hypertension, Idiopathic Pulmonary Fibrosis, Insomnia, Interstitial Cystitis (Painful Bladder Syndrome), Neuropathic Pain, Ocular Hypertension, Open-Angle Glaucoma, Osteoarthritis Pain and Respiratory Tract Infections.

The latest report P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2018, outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
  • The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Asana BioSciences LLC
  • Bayer AG
  • Integral Molecular Inc
  • Merck & Co Inc
  • Pfizer Inc
  • Shionogi & Co Ltd
  • MORE
Introduction

Report Coverage

P2X Purinoceptor 3 (P2RX3) - Overview

P2X Purinoceptor 3 (P2RX3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development

Asana BioSciences LLC

Bayer AG

Integral Molecular Inc

Merck & Co Inc

Neurim Pharmaceuticals Ltd

Pfizer Inc

Shionogi & Co Ltd

P2X Purinoceptor 3 (P2RX3) - Drug Profiles

ASN-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1817080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize P2X3 for Endometriosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gefapixant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSX-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSX-300 Backups - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X3 for Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X3 Receptor for Chronic Pain and Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P2X Purinoceptor 3 (P2RX3) - Dormant Products

P2X Purinoceptor 3 (P2RX3) - Discontinued Products

P2X Purinoceptor 3 (P2RX3) - Product Development Milestones

Featured News & Press Releases

Jun 27, 2018 : BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium

Jun 20, 2018 : BELLUS Health to Present at the 2018 International Cough Symposium

Sep 18, 2017: BELLUS Health's BLU-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models

May 22, 2017: Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough

Apr 27, 2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference

Apr 24, 2017: BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough

Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease

Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease

Sep 05, 2016: Hypertension: releasing the pressure at its source

May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference

Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference

Nov 11, 2015: Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients

Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial

Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome

Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Asana BioSciences LLC, H2 2018

Pipeline by Bayer AG, H2 2018

Pipeline by Integral Molecular Inc, H2 2018

Pipeline by Merck & Co Inc, H2 2018

Pipeline by Neurim Pharmaceuticals Ltd, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by Shionogi & Co Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Asana BioSciences LLC
  • Bayer AG
  • Integral Molecular Inc
  • Merck & Co Inc
  • Neurim Pharmaceuticals Ltd
  • Pfizer Inc
  • Shionogi & Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll